Distribution and risk of human papillomavirus in cervical lesions
- Author:
Han-xiao ZHU
1
;
Piao-piao YE
;
Xu CHEN
;
NANXing-wei
;
Si-jing SU
;
Jia-hua CHEN
;
Ai-xue WU
;
Hong-qin ZHAO
;
Xiao-jian YAN
Author Information
- Publication Type:Journal Article
- Keywords: cervical intraepithelial lesions; cervical tumor; human papillomavirus
- From: Chinese Journal of Practical Gynecology and Obstetrics 2019;35(11):1261-1264
- CountryChina
- Language:Chinese
- Abstract: OBJECTIVE: To analyze the distribution and pathogenicity of 27 HPV(Human papillomavirus)subtypes in cervical lesions.METHODS: A retrospective analysis was carried out in 5735 patients with cervical lesions admitted to the First Affiliated Hospital of Wenzhou Medical University from January 2015 to July 2017,including 997 cases of cervicitis,1568 cases of LSIL(low-grade squamous intraepithelial lesion),2576 cases of HSIL(high-grade squamous intraepithelial lesion)and 594 cases of cervical cancer. The HPV subtypes,histopathological results and ages were obtained for analysis.RESULTS: The positive rates of HPV in cervicitis group,LSIL,HSIL group and cervical cancer group were 57.0%,78.3%,90.5%,and 93.9%(P<0.05)respectively. The five most prevalent HPV types in cervicitis and LSIL group were 52,53,16,58 and 18;in HSIL and cervical cancer they were 16,52,58,33 and 18. The cumulative attribution rates of HPV16,18,58,52,33,31 and 45 in cervicitis,LSIL,HSIL and cervical cancer were 22.2%,38.4%,68.4% and 80.1%,respectively. The incidence of cervical cancer after HPV16,31 and 45 infection was 27.7,14.3 and8.2 times higher than that of cervicitis. Among the 36 cervical cancer tissue samples with negative HPV,8 cases were detected positive by HPV E6/E7 DNA detection.CONCLUSION: HPV16,18,58,52,33,31 and 45 have a high prevalence,cumulative attribution rates and risk values in patients with squamous intraepithelial lesions and cervical cancer. The above-mentioned subtypes of HPV should be included in the prevention and screening of cervical cancer.HPV E6/E7 DNA detection may be a reliable assay for HPV-based screening for prevention of cervical cancer.
